{"id":18709,"date":"2026-09-03T10:15:14","date_gmt":"2026-09-03T10:15:14","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&p=18709"},"modified":"2026-09-04T14:08:34","modified_gmt":"2026-09-04T14:08:34","slug":"what-happens-to-muscle-during-incretin-treatment-exploring-tirzepatides-impact-on-muscle-mass-in-a-preclinical-model-of-obesity","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/what-happens-to-muscle-during-incretin-treatment-exploring-tirzepatides-impact-on-muscle-mass-in-a-preclinical-model-of-obesity\/","title":{"rendered":"What Happens to Muscle During Incretin Treatment? Exploring Tirzepatide\u2019s Impact on Muscle Mass in a Preclinical Model of Obesity"},"content":{"rendered":"\n

Beyond the DIO model, successful obesity therapies require more than just a demonstration of weight loss. In this case study, hear how we, at Sygnature Discovery, provide a comprehensive pre-clinical data package allowing you to select the right drug candidate to take into the clinic. Ultimately, saving your program time and money.
<\/strong><\/p>\n\n\n\n

As the obesity treatment landscape evolves, it\u2019s becoming increasingly important for developers to understand how therapies affect body composition, muscle health and overall function. These insights help differentiate potential drug candidates in a competitive obesity and metabolic therapeutics landscape.<\/p>\n\n\n\n

At Sygnature Discovery, our in vivo<\/em> Pharmacology team helps developers look beyond weight loss alone. By combining clinically relevant diet-induced obesity (DIO) models with advanced body composition, functional and tissue-level assessments, we provide the deeper biological insights needed to truly evaluate candidate quality, reduce development risk and support confident progression decisions.<\/p>\n\n\n\n

In this case study, we demonstrate how our integrated approach revealed that Tirzepatide-induced weight loss was driven predominantly by fat reduction while preserving muscle structure and function.<\/strong><\/p>\n\n\n\n

The Challenge<\/strong><\/h2>\n\n\n\n

Many obesity studies focus primarily on changes in body weight. However, weight loss alone does not reveal whether a therapy is delivering meaningful metabolic benefits.<\/strong><\/p>\n\n\n\n

For obesity therapies, it is increasingly important to understand whether weight loss is driven by reductions in fat mass while preserving lean muscle and physical function. Without additional data on body composition, it can be difficult to determine whether a candidate drug is truly delivering a desirable metabolic profile.<\/p>\n\n\n\n

Our Study<\/strong><\/h2>\n\n\n\n

At Sygnature Discovery, we have over 20 years of experience using Diet Induced Obesity (DIO) mouse models to deliver actionable data and consultations to our clients. Our in vivo<\/em> Pharmacology teams pride themselves on using their expertise to collaborate with our clients to deliver the appropriate in vivo <\/em>models adapted to their desired outcome.<\/p>\n\n\n\n

In the metabolic space, we differentiate ourselves by providing extensive body composition and locomotor data to our clients. Due to our integrated discovery pathway, in vivo<\/em> Pharmacology joins the conversation earlier in the process. This early involvement provides key data that helps our customers identify the most promising candidates sooner. Thus, focusing subsequent effort on molecules that are the most likely to succeed in the clinic. Thereby reducing development risk, avoiding unnecessary investment, and accelerating program progression.<\/p>\n\n\n\n

To demonstrate the power of our integrated workflow, our team evaluated the metabolic effects of Tirzepatide, a dual GLP-1\/GIP receptor agonist, in a DIO mouse model.<\/p>\n\n\n\n

Our study combined multiple, complementary endpoints, including:<\/p>\n\n\n\n